Hypermethylation of the glutathione peroxidase 4 gene promoter is associated with the occurrence of immune tolerance phase in chronic hepatitis B
Authors:
Open Access
- 21 March 2024
- journal article
- research article
- Published by Springer Nature in Virology Journal
- Vol. 21 (1) , 1-12
Abstract
Background: Hepatitis B virus (HBV) infection is a public health problem that seriously threatens human health. This study aimed to investigate the clinical significance of glutathione peroxidase 4(GPX4) in the occurrence and development of chronic hepatitis B (CHB). Methods: A total of 169 participants including 137 patients with CHB and 32 healthy controls (HCs) were recruited. We detected the expression of GPX4 and stimulator of interferon genes (STING) in peripheral blood mononuclear cells (PBMCs) by real-time quantitative polymerase chain reaction (RT-qPCR). The methylation level of GPX4 gene promoter in PBMCs was detected by TaqMan probe-based quantitative methylation-specific PCR (MethyLight). Enzyme-linked immunosorbent assay (ELISA) was performed to detect the serum levels of GPX4, IFN-β, oxidative stress (OS) related molecules, and pro-inflammatory cytokines. Results: The expression levels of GPX4 in PBMCs and serum of CHB patients were lower than those of HCs, but the methylation levels of GPX4 promoter were higher than those of HCs, especially in patients at the immune tolerance phase. STING mRNA expression levels in PBMCs and serum IFN-β levels of patients at the immune activation phase and reactivation phase of CHB were higher than those at other clinical phases of CHB and HCs. GPX4 mRNA expression level and methylation level in PBMCs from patients with CHB had a certain correlation with STING and IFN-β expression levels. In addition, the methylation level of the GPX4 promoter in PBMCs from patients with CHB was correlated with molecules associated with OS and inflammation. Conclusions: GPX4 may play an important role in the pathogenesis and immune tolerance of CHB, which may provide new ideas for the functional cure of CHB.Keywords
Funding Information
- the Natural Science Foundation of Shandong province (ZR2022MH006)
- the national key Research and Development Program of China (2021YFC2301801)
- The National Natural Science Foundation of China (82272313)
This publication has 55 references indexed in Scilit:
- SARS‐CoV‐2, HIV, and HPV: Convergent evolution of selective regulation of cGAS–STING signalingJournal of Medical Virology, 2022
- Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver diseaseActa Pharmaceutica Sinica B, 2022
- NONO Detects the Nuclear HIV Capsid to Promote cGAS-Mediated Innate Immune ActivationCell, 2018
- Species-Specific Deamidation of cGAS by Herpes Simplex Virus UL37 Protein Facilitates Viral ReplicationCell Host & Microbe, 2018
- Lipid Peroxidation Drives Gasdermin D-Mediated Pyroptosis in Lethal Polymicrobial SepsisCell Host & Microbe, 2018
- Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis BCurrent Opinion in Virology, 2018
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidanceHepatology, 2018
- Lipid homeostasis and regulated cell deathCurrent Opinion in Chemical Biology, 2017
- Regulation of Ferroptotic Cancer Cell Death by GPX4Cell, 2014
- Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or CHepatology, 2011